Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Zafgen, Inc. (“Zafgen”) (Nasdaq:ZFGN) between January 12, 2015 and October 16, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The lawsuit alleges that Defendants made misrepresentations about thrombotic adverse events in previous clinical trials of its anti-obesity drug, and leading drug candidate, beloranib. Until October 16, 2015, Zafgen had disclosed only two thrombotic adverse events in one prior clinical trial.
On October 14, 2015, Zafgen issued a statement acknowledging the death of a patient in its ongoing Phase 3 study of beloranib. On October 15, 2015, the Food and Drug Administration informed Zafgen that beloranib had been placed on partial clinical hold. Then on October 16, 2015, Zafgen announced that: (i) the patient who died was receiving beloranib – not a placebo; and (ii) there had been four thrombotic adverse events in prior clinical studies of beloranib – two more than previously reported – as well as two additional, previously undisclosed thrombotic events in ongoing studies.
If you suffered a loss in Zafgen you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
